Benfotiamine
 | |
| Clinical data | |
|---|---|
| Other names | S-benzoylthiamine-O-monophosphate |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.040.906 |
| Chemical and physical data | |
| Formula | C19H23N4O6PS |
| Molar mass | 466.449 g/mol g·mol−1 |
Benfotiamine (rINN, also known as benfotiamine or benphothiamine) is an allithiamin, a naturally-occurring lipophilic form of thiamine. The primary use of this antioxidant is as an "anti-age" supplement. [1] In a trial, benfotiamine lowered AGE by 40%.[2] However, in Germany doctors have been known to combine benfotiamine with pyridoxine hydrochloride and use it to treat patients with nerve damage and nerve pain such as sciatica.
Benfotiamine has shown to be an effective intervention for the treatment of diabetic retinopathy, neuropathy, and nephropathy, possibly because Benfotiamine is a transketolase activator that directs advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the pentose phosphate pathway, thus reducing tissue AGEs.
References
- ^ Reducing Glycation Reactions for Better Health and Longer Life
- ^ J Lin, A Alt, J Liersch, RG Bretzel, M Brownlee (2000 May). "Benfotiamine Inhibits Intracellular Formation of Advanced Glycation End Products in vivo". Diabetes. 49 (Suppl1) (A143).
{{cite journal}}:|access-date=requires|url=(help); Check date values in:|date=(help); Unknown parameter|Ppages=ignored (help)CS1 maint: multiple names: authors list (link)